SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Amgen Inc. (AMGN)
An SI Board Since December 1996
Posts SubjectMarks Bans Symbol
1906 112 0 AMGN
Emcee:  trevor john wilkinson Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1756citi:Initial Take on CMS Bundle Proposal Negative for AMGN & GENZ; Neutral fmopgcw-9/19/2009
1755Coming up are some pivotal events for AMGN....as for options those days are overArthur Radley-9/18/2009
1754Isn't AMGN ramping for FDA Acceptance of Denosumab in October? I'm longRay Rueb-9/18/2009
1753Went long a few shares today @$60.50..data release next week could be driver forArthur Radley-9/18/2009
1752CS: Amgen Inc. (AMGN) OUTPERFORM M. Aberman CP: US$ 60.36 TP: US$ 75 CAP: US$ 61mopgcw18/26/2009
1751here is CS' take: Amgen Inc. (AMGN) OUTPERFORM M. Aberman CP: US$ 59.84 TP: mopgcw-8/18/2009
1750>>Amgen's Vectibix cancer drug shows mixed results NEW YORK, Aug 17 (tuck-8/18/2009
1749CS: Amgen Inc. (AMGN) OUTPERFORM M. Aberman CP: US$ 60.86 TP: US$ 75 CAP: US$ 61mopgcw-8/14/2009
1748CS: Amgen Inc. (AMGN) OUTPERFORM M. Aberman CP: US$ 60.69 TP: US$ 75 CAP: US$ 61mopgcw-8/7/2009
1747CS: Amgen Inc. (AMGN) OUTPERFORM M. Aberman CP: US$ 62.88 TP: US$ 75 CAP: US$ 63bob zagorin-8/4/2009
1746D-mab phase-3 scorecard: siliconinvestor.com It took a long time to prepare thDewDiligence_on_SI-8/4/2009
1745citi: Amgen Inc (AMGN) Strong 2Q09; Raise in Guidance; Dmab Collaboration w/ GSKmopgcw-8/2/2009
1744Amgen Inc. (AMGN) OUTPERFORM M. Aberman CS: CP: US$ 60.77 TP: US$ 75 CAP: US$ 61mopgcw-7/28/2009
1743Seeking Alpha: Amgen, Inc. Q2 2009 Earnings Call Transcript July 27, 2009 5:00 mopgcw-7/28/2009
1742Glaxo eyes Amgen bone drug launch by mid-2010 By Ben Hirschler LONDON (Reuters)nigel bates-7/28/2009
1741Shouda couda wouda.tom pope-7/27/2009
1740WSJ; Amgen Raises Forecast as Profit Climbs By JAY MILLER Amgen Inc.'s semopgcw-7/27/2009
1739There seems to be considerable skepticism re tonight's earnings.tom pope-7/27/2009
1738CS: Amgen Inc. (AMGN) OUTPERFORM M. Aberman CP: US$ 60.92 TP: US$ 72 CAP: US$ 61mopgcw-7/27/2009
1737CS: Amgen Inc. (AMGN) OUTPERFORM M. Aberman CP: US$ 52.23 TP: US$ 72 CAP: US$ 52mopgcw-7/8/2009
1736citi: Amgen Inc (AMGN) Will Dmab Be Better Than Zometa in Prostate Cancer? Ph 2 mopgcw-7/3/2009
1735Are Short Drug Patents Hurting Patients? Matthew Herper, 05.11.09, 08:40 AM EDT JGoren-5/11/2009
1734CS: Amgen Inc. (AMGN) OUTPERFORM M. Aberman CP: US$ 46.82 TP: US$ 62 CAP: US$ 47mopgcw-4/24/2009
1733Attack Of The Zombie Biotechs Steve Brozak, Larry Jindra and Dan Mallin , 04.02.JGoren-4/2/2009
1732DJ: JPMorgan analysts raised their rating of biotechnology giant Amgen Inc. to omopgcw-3/29/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News